Literature DB >> 9405998

Determination of in vitro drug sensitivity to a panel of cystostatic drugs and interferon alpha-2b in patients with renal cell carcinoma.

S Küpeli1, M Beksac, B Küpeli, S Baltaci, O Süzer.   

Abstract

Fresh operative cells from 27 renal cell carcinomas (RCC) were cultured in vitro for the determination of in vitro drug sensitivity. Two samples were not culturable. Incubation was carried out in triplicate in the presence and absence of various concentrations of chemotherapeutic agents. Sensitivity of the tumour cells to interferon-alpha (IFN-alpha), cisplatin (CDDP), mitomycin C (MMC), vinblastine (VBL), doxorubicin (DOX), etoposide (ETOP), bleomycin (BLM), vincristine (VCR) were tested by a colorimetric assay using MTT. A preexposure viability over 75% was essential for in vitro drug sensitivity assay (IVDSA). Sensitivity was determined by a more than 50 +/- 2 SD% reduction from the control absorbance. All eight drugs in their low concentrations exhibited cell proliferation inhibition in 0-12% of RCCs. On the other hand, IFN-alpha in its higher concentration (60 IU/ml) was effective in 88% of RCCs. After IFN, CDDP was found to be the second most effective drug in its higher concentration (36% efficacy). The results indicate that IFN appears to be the most effective in vitro agent in our 25 RCCs and the clinical trials either as a monotherapy or multiple combinations of various agents should include IFNs for the treatment of RCC.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9405998     DOI: 10.1007/bf02551107

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  20 in total

1.  Phase II study of interferon-alpha and chemotherapy (5-fluorouracil and mitomycin C) in metastatic renal cell cancer.

Authors:  A Sella; C J Logothetis; K Fitz; F H Dexeus; R Amato; R Kilbourn; S Wallace
Journal:  J Urol       Date:  1992-03       Impact factor: 7.450

2.  Cancer statistics, 1987.

Authors:  E Silverberg; J Lubera
Journal:  CA Cancer J Clin       Date:  1987 Jan-Feb       Impact factor: 508.702

Review 3.  Therapeutic options in renal cell carcinoma.

Authors:  A C Buzaid; M B Todd
Journal:  Semin Oncol       Date:  1989-02       Impact factor: 4.929

4.  Adjunctive treatment of renal cell carcinoma.

Authors:  J E Pontes
Journal:  Int Adv Surg Oncol       Date:  1983

Review 5.  Interferon alpha-2a and vinblastine in the treatment of metastatic renal carcinoma.

Authors:  M Rizzo; R Bartoletti; C Selli; A Sicignano; D Criscuolo
Journal:  Eur Urol       Date:  1989       Impact factor: 20.096

Review 6.  Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review.

Authors:  S Wadler; E L Schwartz
Journal:  Cancer Res       Date:  1990-06-15       Impact factor: 12.701

7.  Predictive value of the fluorescent cytoprint assay (FCA): a retrospective correlation study of in vitro chemosensitivity and individual responses to chemotherapy.

Authors:  L A Leone; P A Meitner; T J Myers; W R Grace; W H Gajewski; H J Fingert; B Rotman
Journal:  Cancer Invest       Date:  1991       Impact factor: 2.176

8.  In vitro sensitivity testing of human renal cell carcinoma with cytostatic agents and interferon alpha-2a.

Authors:  W de Riese; E Allhoff; C G Stief; G Lenis; R Schlick; S Liedke; P Anton; U Jonas
Journal:  Urol Res       Date:  1991

Review 9.  In vitro predictive testing: the sulfonamide era.

Authors:  D D Von Hoff
Journal:  Int J Cell Cloning       Date:  1987-05

10.  Effect of alpha-interferon alone and combined with other antineoplastic agents on renal cell carcinoma determined by the tetrazolium microculture assay.

Authors:  Y Homma; Y Aso
Journal:  Eur Urol       Date:  1994       Impact factor: 20.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.